THE RESULTS OF USING THE CANRISK TOOL IN DETERMINING THE RISK OF BREAST CANCER

Thu Hương Vũ , Thị Trang Nguyễn, Lê Huy Trịnh , Thanh Long Nguyễn, Thị Lan Anh Lương , Thị Kim Thanh Hồ

Main Article Content

Abstract

Objective: This study aims to evaluate the effectiveness and practical applicability of the CanRisk tool in assessing the risk of breast cancer. Methods: The research involved the retrospective analysis of medical records of 40 individuals who had been diagnosed with breast cancer. The Canrisk tool was utilized to calculate breast cancer risk based on input data, including information about risk factors and genetic mutations  Result: Among the 40 cases of breast cancer confirmed by histopathology, the Canrisk tool identified 7 cases (17.5%) as having a high risk of breast cancer. The remaining cases were categorized as being in the population risk group. In one instance, a familial breast cancer case was identified, wherein the subject and their relatives carried the BRCA1/2 gene mutation. This prompted a recommendation for genetic testing, revealing that all tested individuals with the mutation carried the BRCA1 mutation. Conclusion: The outcomes of this preliminary study demonstrate CanRisk's capacity to forecast the prevalence of BRCA1/2 gene mutations in cases of familial breast cancer in Vietnam. It proves effective in gauging breast cancer risk among individuals carrying BRCA1/2 gene mutations, yet it has not proven to be notably superior to conventional screening methods in all cases.

Article Details

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33. doi:10.3322/caac.21654
2. Lee AJ, Cunningham AP, Kuchenbaecker KB, et al. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer. 2014;110(2):535-545. doi:10.1038/bjc.2013.730
3. National Collaborating Centre for Cancer (UK). Familial Breast Cancer: Classification and Care of People at Risk of Familial Breast Cancer and Management of Breast Cancer and Related Risks in People with a Family History of Breast Cancer. National Collaborating Centre for Cancer (UK); 2013. Accessed October 3, 2023. http://www.ncbi.nlm.nih.gov/books/NBK247567/
4. Lakeman IMM, Rodríguez-Girondo M, Lee A, et al. Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort. Genet Med Off J Am Coll Med Genet. 2020;22(11): 1803-1811. doi: 10.1038/s41436-020-0884-4
5. Pal Choudhury P, Brook MN, Hurson AN, et al. Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. Breast Cancer Res BCR. 2021;23(1):22. doi: 10.1186/ s13058-021-01399-7
6. Esserman LJ, Thompson IM, Reid B, et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 2014;15(6): e234-242. doi: 10.1016/S1470-2045 (13)70598-9
7. Antoniou AC, Hardy R, Walker L, et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet. 2008;45(7):425-431. doi: 10.1136/jmg.2007.056556
8. Fischer C, Kuchenbäcker K, Engel C, et al. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium. J Med Genet. 2013;50(6):360-367. doi:10.1136/jmedgenet-2012-101415